Cannabinoids can be said to help those that suffer from different types of pains, diseases and illnesses. However, could they provide a protective system to prevent an initial illness in the first place? Due to the growing choice of medical cannabis now being used to treat patients such as cancer sufferers, researchers are closely examining the other potentials that it may garner. Studies currently have a debatable argument for both the opposing and approving points in using medicinal cannabis for medical purposes.
This paper will look at how cannabinoids can form a protective layer around the body to fend off human dysfunctions.
Here is the full scientific article if you wish to download it.
The animal body has a highly advanced immune network which protects against continuous infiltrating protein melees and hopes to stop, attenuating or fixing the done damage. It is known that through evolution analogous biological safety systems have been advanced against non-protein fights. There is surface rising reports that lipid endocannabinoid transmissioning through cannabinoid 2 (CB2) receptors may hold an example/part of such a network system/armamentarium. Inflammation/tissue injury triggers rapid elevations in local endocannabinoid levels, which in turn mediate transmissioning reactions in immune and other cells alternating their critical methods. Alterations in endocannabinoid accumulations and/or CB2receptor expressions have been said to be in almost all disorders affecting humans, ranging from cardiovascular, gastrointestinal, liver, kidney, neurodegenerative, psychiatric, bone, skin, auto-immune, lung disorders to pain and cancer, and the changing slightly CB2 receptor activity holds vast therapeutic possibilities in these pathologies.
While CB2 receptor triggering in general controls immunosuppressive impacts, which limit inflammation and related tissue damage in large number of pathological syndromes, in some disease conditions triggering of the CB2 receptor may add to or even activate tissue damage, which will also be thought out alongside the protective acts of the CB2 receptor tinkering with endocannabinoids or synthetic agonists, and the possible biological actions in cahoots with these effects.
Overall, multiple lines of evidence are embodied that support the outlook that lipid endocannabinoid transmissioning through CB2 receptors holds high an aspect of the mammalian protective tool kit, and its alteration by either selective CB2 receptor agonists or inverse agonists/antagonists (depending on the syndrome and its stage) holds rare therapeutic potential in a vast amount of diseases.
In recent times, a huge number of novel synthetic and natural CB2 receptor agonists have been investigated thoroughly, handing hope that some of the above discussed preclinical conclusions could also be truncated into clinical treatments in the close present to ease human sufferings.